Repurposing atovaquone: targeting mitochondrial complex III and OXPHOS to eradicate cancer stem cells

Atovaquone is an FDA-approved anti-malarial drug, which first became clinically available in the year 2000. Currently, its main usage is for the treatment of pneumocystis pneumonia (PCP) and/or toxoplasmosis in immune-compromised patients. Atovaquone is a hydroxy-1,4-naphthoquinone analogue of ubiqu...

Celý popis

Podrobná bibliografia

Vydané v:	Oncotarget Ročník 7; číslo 23; s. 34084 - 34099
Hlavní autori:	Fiorillo, Marco, Lamb, Rebecca, Tanowitz, Herbert B, Mutti, Luciano, Krstic-Demonacos, Marija, Cappello, Anna Rita, Martinez-Outschoorn, Ubaldo E, Sotgia, Federica, Lisanti, Michael P
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States 07.06.2016
Predmet:	Antimalarials - pharmacology Antineoplastic Agents - pharmacology Atovaquone - pharmacology Drug Repositioning Electron Transport Complex III - antagonists & inhibitors Humans MCF-7 Cells Neoplastic Stem Cells - drug effects Oxidative Phosphorylation - drug effects tumor-initiating cells (TICs) OXPHOS cancer stem-like cells (CSCs) atovaquone mitochondria
ISSN:	1949-2553
On-line prístup:	Zistit podrobnosti o prístupe
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!